Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2445540 | 0.91 | SYK (0.32) | SYK | |
| SCHEMBL13355576 | 0.79 | MAPT (0.43) | SYKGPR119 | |
| SCHEMBL2484835 | 0.79 | SYK (0.37) | SYKBRD4PDE3BPDE3A | |
| SCHEMBL2481477 | 0.78 | TNK2 (0.38) | SYK | |
| SCHEMBL2444641 | 0.78 | SYK (0.39) | SYK | |
| SCHEMBL13355536 | 0.78 | SYK (0.39) | SYKSTK17ABRD4PDE3BPDE3A | |
| SCHEMBL2475127 | 0.78 | ADORA2A (0.35) | SYKBRD4 | |
| SCHEMBL2480301 | 0.77 | LRRK2 (0.39) | SYK | |
| SCHEMBL2843371 | 0.76 | SYK (0.44) | SYK | |
| SCHEMBL2481672 | 0.76 | ROCK2 (0.35) | SYKGPR119BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188101-B2 | Dihydropyridopyrimidines for the treatment of AB-related pathologies | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | disclosed |
| US-20100130495-A1 | COMPOUNDS 563 | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130495-A1 | COMPOUNDS 563 | BACE1, PSEN1, PSEN2 | SYK 641/4885STK17A 1316/4885GPR119 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.